Bioinformatics-based investigation of the therapeutic potential of Tongxinluo capsule in acute myocardial infarction

doi:10.5246/jcps.2024.11.075

Abstract

Abstract:

Acute myocardial infarction (AMI) is associated with a challenging prognosis. Notably, the Tongxinluo capsule (TXL), a proprietary Chinese medicine, has garnered attention for its potential therapeutic effects. This study aimed to elucidate the concealed pharmacological benefits of TXL in AMI patients and identify pertinent immunological targets. In the GSE66360 dataset, 172 upregulated genes and 16 downregulated genes were discerned. Subsequently, 803 key targets of TXL were meticulously sifted through the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and Herbal Ingredients’ Targets (HERB) databases. The intersection of these datasets was determined using Venn diagrams. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses unveiled that these genes were predominantly associated with the NF-kappa B signaling pathway, TNF signaling pathway, IL-17 signaling pathway, and other signaling cascades. The extent of immune infiltration between AMI and control samples was assessed using Cibersort, and Spearman’s rank correlation was employed to explore the relationship between immune cells and the amalgamated genes. This investigation revealed that the amelioration of AMI with TXL might be linked to an augmentation in mast cell-activated cells and neutrophil invasion. The Weighted Gene Co-expression Network Analysis (WGCNA) identified gene modules strongly correlated with 22 immune cells. These modules were further scrutinized using the Cibersort algorithm, leading to the recognition of eight genes deemed pivotal as potential novel molecular markers for TXL treatment of AMI. The infiltration of defense cells was also found to exert a significant impact. This study contributed to our understanding of the pharmacological mechanisms of TXL and provided valuable insights for future investigations into potential targets for AMI immunotherapy.

Key words: one, Bioinformatics, Acute myocardial infarction, Immune infiltration, Proprietary Chinese medicine

Supporting:

Jingjing Su, Kangkang Su, Yanping Song, Lihui Hao, Xing Wang, Linquan Yang, Chao Wang, Shuxia Chen, Jian Gu. Bioinformatics-based investigation of the therapeutic potential of Tongxinluo capsule in acute myocardial infarction[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(11): 1040-1057.

Figures/Tables 9

References 52

[1]	Danchin, N.; Popovic, B.; Puymirat, E.; Goldstein, P.; Belle, L.; Cayla, G.; Roubille, F.; Lemesle, G.; Ferrières, J.; Schiele, F.; Simon, T.; Investigators, T.F.M. Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme. Eur. Heart J. 2020, 41, 858–866.
[2]	Thrane, P.G.; Kristensen, S.D.; Olesen, K.K.W.; Mortensen, L.S.; Bøtker, H.E.; Thuesen, L.; Hansen, H.S.; Abildgaard, U.; Engstrøm, T.; Andersen, H.R.; Maeng, M. 16-year follow-up of the Danish Acute Myocardial Infarction 2 (DANAMI-2) trial: primary percutaneous coronary intervention vs. fibrinolysis in ST-segment elevation myocardial infarction. Eur. Heart J. 2020, 41, 847–854.
[3]	Taqueti, V.R.; Mitchell, R.N.; Lichtman, A.H. Protecting the pump: controlling myocardial inflammatory responses. Annu. Rev. Physiol. 2006, 68, 67–95.
[4]	Granger, D.N.; Korthuis, R.J. Physiologic mechanisms of postischemic tissue injury. Annu. Rev. Physiol. 1995, 57, 311–332.
[5]	Vinten-Johansen, J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc. Res. 2004, 61, 481–497.
[6]	Yang, Y.J.; Li, X.D.; Chen, G.H.; Xian, Y.; Zhang, H.T.; Wu, Y.; Yang, Y.M.; Wu, J.H.; Wang, C.T.; He, S.H.; Wang, Z.; Wang, Y.X.; Wang, Z.F.; Liu, H.; Wang, X.P.; Zhang, M.Z.; Zhang, J.; Li, J.; An, T.; Guan, H.; Li, L.; Shang, M.X.; Yao, C.; Han, Y.L.; Zhang, B.L.; Gao, R.L.; Peterson, E.D.; Investigators, C.A. Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardial infarction: the CTS-AMI randomized clinical trial. JAMA. 2023, 330, 1534–1545.
[7]	Barrett, T.; Wilhite, S.E.; Ledoux, P.; Evangelista, C.; Kim, I.F.; Tomashevsky, M.; Marshall, K.A.; Phillippy, K.H.; Sherman, P.M.; Holko, M.; Yefanov, A.; Lee, H.; Zhang, N.; Robertson, C.L.; Serova, N.; Davis, S.; Soboleva, A. NCBI GEO: archive for functional genomics data sets: update. Nucleic Acids Res. 2013, 41, D991–D995.
[8]	Fang, S.S.; Dong, L.; Liu, L.; Guo, J.C.; Zhao, L.H.; Zhang, J.Y.; Bu, D.C.; Liu, X.K.; Huo, P.P.; Cao, W.C.; Dong, Q.Y.; Wu, J.R.; Zeng, X.X.; Wu, Y.; Zhao, Y. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 2021, 49, D1197–D1206.
[9]	Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; Xu, X.; Li, Y.; Wang, Y.; Yang, L. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Biomolecules. 2014, 6, 13.
[10]	UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nat. Commun. 2021, 49, D480–D489.
[11]	Liao, Y.X.; Wang, J.; Jaehnig, E.J.; Shi, Z.A.; Zhang, B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019, 47, W199–W205.
[12]	Szklarczyk, D.; Gable, A.L.; Nastou, K.C.; Lyon, D.; Kirsch, R.; Pyysalo, S.; Doncheva, N.T.; Legeay, M.; Fang, T.; Bork, P.; Jensen, L.J.; von Mering, C. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021, 49, D605–D612.
[13]	Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.G.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Meth. 2015, 12, 453–457.
[14]	Langfelder, P.; Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008, 9, 559.
[15]	White, H.D.; Thygesen, K.; Alpert, J.S.; Jaffe, A.S. Clinical implications of the Third Universal Definition of Myocardial Infarction. Heart. 2014, 100, 424–432.
[16]	Frangogiannis, N.G. The inflammatory response in myocardial injury, repair, and remodelling. Nat. Rev. Cardiol. 2014, 11, 255–265.
[17]	Westman, P.C.; Lipinski, M.J.; Luger, D.; Waksman, R.; Bonow, R.O.; Wu, E.; Epstein, S.E. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 2016, 67, 2050–2060.
[18]	Mezzaroma, E.; Toldo, S.; Farkas, D.; Seropian, I.M.; Van Tassell, B.W.; Salloum, F.N.; Kannan, H.R.; Menna, A.C.; Voelkel, N.F.; Abbate, A. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc. Natl. Acad. Sci. USA. 2011, 108, 19725–19730.
[19]	Li, M.; Li, C.; Chen, S.; Sun, Y.; Hu, J.; Zhao, C.; Qiu, R.; Zhang, X.; Zhang, Q.; Tian, G.; Shang, H. Potential effectiveness of Chinese patent medicine Tongxinluo capsule for secondary prevention after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2018, 9, 830.
[20]	Qi, Y.; Liu, W.; Yan, X.; Zhang, C.; Zhang, C.; Liu, L.; Zheng, X.; Suo, M.; Ti, Y.; Ni, M.; Zhang, M.; Bu, P. Tongxinluo may alleviate inflammation and improve the stability of atherosclerotic plaques by changing the intestinal flora. Front. Pharmacol. 2022, 13, 805266.
[21]	Li, G.; Xu, Q.; Han, K.; Yan, W.; Huang, C. Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases. Biosci. Rep. 2020, 40, BSR20201349.
[22]	Yu, H.; Lin, L.B.; Zhang, Z.Q.; Zhang, H.Y.; Hu, H.B. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct. Target. Ther. 2020, 5, 209.
[23]	Yang, S.; Li, F.; Lu, S.; Ren, L.; Bian, S.; Liu, M.; Zhao, D.; Wang, S.; Wang, J. Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF-kappaB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J. Ethnopharmacol. 2022, 283, 114739.
[24]	Wu, Z.; Zhang, Z.; Lei, Z.; Lei, P. CD14: biology and role in the pathogenesis of disease. Cytokine Growth Factor Rev. 2019, 48, 24–31.
[25]	An, D.; Hao, F.; Zhang, F.; Kong, W.; Chun, J.; Xu, X.; Cui, M.Z. CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation. J. Biol. Chem. 2017, 292, 14391–14400.
[26]	de Carvalho, D.C.; Fonseca, F.A.H.; Izar, M.C.O.; Silveira, A.L.P.A.; Tuleta, I.D.; do Amaral, J.B.; Neves, L.M.; Bachi, A.L.L.; França, C.N. Monocytes presenting a pro-inflammatory profile persist in patients submitted to a long-term pharmacological treatment after acute myocardial infarction. Front. Physiol. 2022, 13, 1056466.
[27]	Choudhary, D.; Jansson, I.; Stoilov, I.; Sarfarazi, M.; Schenkman, J.B. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos. Biol. Fate Chem. 2004, 32, 840–847.
[28]	Qi, L.; Qi, Q.B.; Prudente, S.; Mendonca, C.; Andreozzi, F.; di Pietro, N.; Sturma, M.; Novelli, V.; Mannino, G.C.; Formoso, G.; Gervino, E.V.; Hauser, T.H.; Muehlschlegel, J.D.; Niewczas, M.A.; Krolewski, A.S.; Biolo, G.; Pandolfi, A.; Rimm, E.; Sesti, G.; Trischitta, V.; Hu, F.; Doria, A. Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. JAMA. 2013, 310, 821–828.
[29]	Eelen, G.; Dubois, C.; Cantelmo, A.R.; Goveia, J.; Brüning, U.; DeRan, M.; Jarugumilli, G.; van Rijssel, J.; Saladino, G.; Comitani, F.; Zecchin, A.; Rocha, S.; Chen, R.Y.; Huang, H.L.; Vandekeere, S.; Kalucka, J.; Lange, C.; Morales-Rodriguez, F.; Cruys, B.; Treps, L.; Ramer, L.; Vinckier, S.; Brepoels, K.; Wyns, S.; Souffreau, J.; Schoonjans, L.; Lamers, W.H.; Wu, Y.; Haustraete, J.; Hofkens, J.; Liekens, S.; Cubbon, R.; Ghesquière, B.; Dewerchin, M.; Gervasio, F.L.; Li, X.R.; van Buul, J.D.; Wu, X.; Carmeliet, P. Role of glutamine synthetase in angiogenesis beyond glutamine synthesis. Nature. 2018, 561, 63–69.
[30]	Falk, E.; Nakano, M.; Bentzon, J.F.; Finn, A.V.; Virmani, R. Update on acute coronary syndromes: the pathologists’ view. Eur. Heart J. 2013, 34, 719–728.
[31]	Li, T.; Li, X.; Feng, Y.; Dong, G.; Wang, Y.; Yang, J. The role of matrix metalloproteinase-9 in atherosclerotic plaque instability. Mediat. Inflamm. 2020, 2020, 3872367.
[32]	Cozen, A.E.; Moriwaki, H.; Kremen, M.; DeYoung, M.B.; Dichek, H.L.; Slezicki, K.I.; Young, S.G.; Véniant, M.; Dichek, D.A. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation. 2004, 109, 2129–2135.
[33]	Pan, Q.; Hui, D.; Hu, C. Associations of CD14 variants with the triglyceride levels and risk of myocardial infarction in an Eastern Chinese Han population. Int. Immunopharmacol. 2021, 99, 108041.
[34]	Majchrzak-Gorecka, M.; Majewski, P.; Grygier, B.; Murzyn, K.; Cichy, J. Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response. Cytokine Growth Factor Rev. 2016, 28, 79–93.
[35]	Nernpermpisooth, N.; Prompunt, E.; Kumphune, S. An in vitro endothelial cell protective effect of secretory leukocyte protease inhibitor against simulated ischaemia/reperfusion injury. Exp. Ther. Med. 2017, 14, 5793–5800.
[36]	Sarecka-Hujar, B.; Zak, I.; Krauze, J. Interactions between rs5498 polymorphism in the ICAM1 gene and traditional risk factors influence susceptibility to coronary artery disease. Clin. Exp. Med. 2009, 9, 117–124.
[37]	Grebe, A.; Hoss, F.; Latz, E. NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ. Res. 2018, 122, 1722–1740.
[38]	Sager, H.B.; Heidt, T.; Hulsmans, M.; Dutta, P.; Courties, G.; Sebas, M.; Wojtkiewicz, G.R.; Tricot, B.; Iwamoto, Y.; Sun, Y.; Weissleder, R.; Libby, P.; Swirski, F.K.; Nahrendorf, M. Targeting interleukin-1β reduces leukocyte production after acute myocardial infarction. Circulation. 2015, 132, 1880–1890.
[39]	Ngkelo, A.; Richart, A.; Kirk, J.A.; Bonnin, P.; Vilar, J.; Lemitre, M.; Marck, P.; Branchereau, M.; Le Gall, S.; Renault, N.; Guerin, C.; Ranek, M.J.; Kervadec, A.; Danelli, L.; Gautier, G.; Blank, U.; Launay, P.; Camerer, E.; Bruneval, P.; Menasche, P.; Heymes, C.; Luche, E.; Casteilla, L.; Cousin, B.; Rodewald, H.R.; Kass, D.A.; Silvestre, J.S. Mast cells regulate myofilament calcium sensitization and heart function after myocardial infarction. J. Exp. Med. 2016, 213, 1353–1374.
[40]	Jung, K.; Kim, P.; Leuschner, F.; Gorbatov, R.; Kim, J.K.; Ueno, T.; Nahrendorf, M.; Yun, S.H. Endoscopic time-lapse imaging of immune cells in infarcted mouse hearts. Circ Res. 2013, 112, 891–899.
[41]	Li, W.; Hsiao, H.M.; Higashikubo, R.; Saunders, B.T.; Bharat, A.; Goldstein, D.R.; Krupnick, A.S.; Gelman, A.E.; Lavine, K.J.; Kreisel, D. Heart-resident CCR2⁺ macrophages promote neutrophil extravasation through TLR9/MyD88/CXCL5 signaling. JCI Insight. 2016, 1, 87315.
[42]	Liu, J.Q.; Zhao, M.; Zhang, Z.; Cui, L.Y.; Zhou, X.; Zhang, W.; Chu, S.F.; Zhang, D.Y.; Chen, N.H. Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-κB signaling and modulation of M1/M2 polarization. Acta Pharmacol. Sin. 2020, 41, 523–534.
[43]	Ma, Y.G.; Mouton, A.J.; Lindsey, M.L. Cardiac macrophage biology in the steady-state heart, the aging heart, and following myocardial infarction. Transl. Res. 2018, 191, 15–28.
[44]	Chen, Y.; Waqar, A.B.; Nishijima, K.; Ning, B.; Kitajima, S.; Matsuhisa, F.; Chen, L.; Liu, E.; Koike, T.; Yu, Y.; Zhang, J.; Chen, Y.E.; Sun, H.; Liang, J.; Fan, J. Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits. Eur. Heart J. Case Rep. 2020, 24, 4261–4274.
[45]	Im, D.S. Pro-resolving effect of ginsenosides as an anti-inflammatory mechanism of Panax ginseng. Biomolecules. 2020, 10, E444.
[46]	Sun, K.; Su, C.; Li, W.; Gong, Z.; Sha, C.; Liu, R. Quality markers based on phytochemical analysis and anti-inflammatory screening: an integrated strategy for the quality control of Dalbergia odorifera by UHPLC-Q-Orbitrap HRMS. Phytomedicine. 2021, 84, 153511.
[47]	Ham, S.A.; Hwang, J.S.; Kang, E.S.; Yoo, T.; Lim, H.H.; Lee, W.J.; Paek, K.S.; Seo, H.G. Ethanol extract of Dalbergia odorifera protects skin keratinocytes against ultraviolet B-induced photoaging by suppressing production of reactive oxygen species. Biosci. Biotechnol. Biochem. 2015, 79, 760–766.
[48]	Tao, Y.; Wang, Y. Bioactive sesquiterpenes isolated from the essential oil of Dalbergia odorifera T. Chen. Fitoterapia. 2010, 81, 393–396.
[49]	Fan, Z.M.; Wang, D.Y.; Yang, J.M.; Lin, Z.X.; Lin, Y.X.; Yang, A.L.; Fan, H.; Cao, M.; Yuan, S.Y.; Liu, Z.J.; Zhou, X.; Wang, Y.H. Dalbergia odorifera extract promotes angiogenesis through upregulation of VEGFRs and PI3K/MAPK signaling pathways. J. Ethnopharmacol. 2017, 204, 132–141.
[50]	Li, X.; Wu, L.; Liu, W.; Jin, Y.; Chen, Q.; Wang, L.; Fan, X.; Li, Z.; Cheng, Y. A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action. PLoS One. 2014, 9, e95004.
[51]	Cai, M.; Yu, Z.; Wang, L.; Song, X.; Zhang, J.; Zhang, Z.; Zhang, W.; Li, W.; Xiang, J.; Cai, D. Tongxinluo reduces brain edema and inhibits post-ischemic inflammation after middle cerebral artery occlusion in rats. J. Ethnopharmacol. 2016, 181, 136–145.
[52]	Wang, C.H.; Wang, R.; Cheng, X.M.; He, Y.Q.; Wang, Z.T.; Wu, C.; Cao, J. Comparative pharmacokinetic study of paeoniflorin after oral administration of decoction of Radix Paeoniae Rubra and Radix Paeoniae Alba in rats. J. Ethnopharmacol. 2008, 117, 467–472.